Best Practices for the Management of Non-Small Cell Lung Cancer


Program Dates: December 1, 2018 – November 30, 2019
Credits: 1.0 AMA PRA Category 1 Credits™ and 1.0 CNE contact hours


Best Practices for the Management of Non-Small Cell Lung Cancer

Program Overview

This CME/CNE activity will review recent advances in patients with non-small cell lung cancer (NSCLC) incorporating data presented at the European Society For Medical Oncology (ESMO) 2018 Conference in Munich, Germany. The three expert faculty will analyze clinical trial data on the current science and emerging best practices for the treatment of NSCLC. The faculty will also discuss how to utilize biomarker testing and gene mutations to more effectively treat patients with NSCLC. Upon completion of this activity, learners will gain knowledge on how to implement emerging therapeutics of NSCLC to treat patients and ultimately improve patient outcomes.

Target Audience

Oncologists, internists, primary care physicians, nurse practitioners, physician assistants’ and other advance practice healthcare professionals involved in the management of patients with NSCLC

Learning Objectives

1. Apply the science of NSCLC, including biomarker testing and gene mutations to more effectively treat patients
2. Analyze clinical trial data for current and emerging therapeutics for the treatment of NSCLC, incorporating data presented at ESMO 2018

Faculty

Tom StinchcombeThomas E. Stinchcombe, MD
Professor of Medicine
Duke Cancer Institute
Durham, NC

 

 

 

 Hossein Borghaei, MS, DOHosseinBorghaei640x860
Professor and Chief, Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA

 

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

FacultyRelationship Identified With:
Thomas E. Stinchcombe, M.D.Consultant/Advisor: Genentech, Takeda Oncology, Astra Zeneca
Hossein Borghaei, M.S., D.O.Consultant/Advisor: BMS, Lilly, Genentech, Celgene, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, AxiomGrant/Research Support: Millennium, Merck/Celgene, BMS/LillySpeaker’s Bureau: University of Pennsylvania, CAR T ProgramTakeda

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour). AcademicCME’s ANCC provider number is P0491.

Financial Support

This activity has been supported by an independent educational grant from Takeda Oncology; Lilly USA, LLC and Incyte Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Takeda Oncology; Lilly USA, LLC and Incyte Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].

BUTTON

Co-provided by: AcademicCME-web